Share

EORTC endorses the European Code of Cancer Practice

The European Code of Cancer Practice (The Code), an initiative coordinated by European Cancer organisation, is a citizen and patient-centred manifesto of the core requirements for good clinical cancer practice, in order to improve outcomes for all of Europe’s cancer patients.  It has been co-produced by a team of cancer patients, patient advocates and cancer professionals.  It has its origins in the European Cancer Patient Bill of Rights, which was launched in the European Parliament on World Cancer Day 2014 and won the prestigious 2018 European Health Award.

The Code focusses on informing and assisting cancer patients at all stages of their cancer journey. It sets out a series of 10 key overarching rights, and in particular, signposting what patients should expect from their health system, in order for them to achieve the best possible outcomes.  It is an empowerment tool to ensure the best available care is delivered for European citizens and patients. Each of the 10 overarching rights is linked to three questions that a patient/parent/guardian may choose to ask their healthcare professionals.

“The European Code of Cancer Practice represents an important step forward towards patient centred approaches for research and care, bringing together an unprecedented range of stakeholders sharing the same values to push forward the standards of treatment and care of cancer patients in Europe,” said Dr Denis Lacombe, EORTC Director General. “EORTC contributes, with great enthusiasm and pride, to the coordinated efforts of European Cancer Organisation.”

Read more about the code here.

Back to news list

Related News

  • EORTC and Immunocore announce enrolment of first patient onto the only active Phase 3 adjuvant trial in uveal melanoma

  • Minister F. Vandenbroucke visits EORTC Headquarters to strengthen collaborative efforts in clinical cancer research

  • IMMUcan has completed patient enrolment

  • EORTC SPRINT clinical cancer study receives support from Rising Tide Foundation to reduce the burden for patients

  • Pink October at EORTC: Over 60 years of impactful breast cancer research

  • Spotlight on ENA 2024 News

  • Do regulations and policies undermine the social value of independent academic research?

  • EORTC Quality of Life Group’s participation to ISOQOL 2024

  • New Insights into Glioblastoma Treatment for Older Adults Patients

  • TOPGEAR trial results show no significant benefit of preoperative chemoradiotherapy on long term survival